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Introduction
In order to combat infections and cancer the human body is equipped with an
innate and adaptive immune system. The two systems are highly intertwined and
closely collaborate with a bridging role for antigen-presenting cells e.g., dendritic
cells. Their differences and commonalities are depicted in Table 1 (for more detailed
reviews see references1-3). After birth, the immune system evolves from and is
shaped by exposure to foreign antigens, which for the most part come from
microbes belonging to the gut microbiota.4 Gradually, an immune armamentarium
is build which, by virtue of memory properties, acts increasingly specifically, rapid-
ly and efficiently. Immune memory has in the past been attributed solely to the
adaptive immune system, but recently the paradigm has shifted with evidence
showing that the innate immune system possesses the capacity for immunological
memory, designated ‘trained immunity’.5 This feature is crucial for organisms that
In hematological malignancies complex interactions exist betweenthe immune system, microorganisms and malignant cells. On onehand, microorganisms can induce cancer, as illustrated by specific
infection-induced lymphoproliferative diseases such as Helicobacter
pylori-associated gastric mucosa-associated lymphoid tissue lymphoma.
On the other hand, malignant cells create an immunosuppressive envi-
ronment for their own benefit, but this also results in an increased risk
of infections. Disrupted innate immunity contributes to the neoplastic
transformation of blood cells by several mechanisms, including the
uncontrolled clearance of microbial and autoantigens resulting in chron-
ic immune stimulation and proliferation, chronic inflammation, and
defective immune surveillance and anti-cancer immunity. Restoring
dysfunction or enhancing responsiveness of the innate immune system
might therefore represent a new angle for the prevention and treatment
of hematological malignancies, in particular lymphoid malignancies and
associated infections. Recently, it has been shown that cells of the
innate immune system, such as monocytes/macrophages and natural
killer cells, harbor features of immunological memory and display
enhanced functionality long-term after stimulation with certain
microorganisms and vaccines. These functional changes rely on epige-
netic reprogramming and have been termed ‘trained immunity’. In this
review the concept of ‘trained immunity’ is discussed in the setting of
lymphoid malignancies. Amelioration of infectious complications and
hematological disease progression can be envisioned to result from the
induction of trained immunity, but future studies are required to prove
this exciting new hypothesis.
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ABSTRACT
have no adaptive immune response, e.g., plants and inver-
tebrates, but it also exists in humans, where it might be of
special benefit in neonates that have yet to develop a
mature adaptive immune repertoire.6 Importantly, 'train-
ing' of the innate immune system by the use of vaccina-
tion, resulting in increased immune activation, has been
shown feasible. Hopefully these insights can be exploited
in the near future for the design of new treatments for
immunodeficiencies, infections and cancer.7
Currently, immunotherapies used for the treatment of
hematological malignancies have focused on the adaptive
immune system, mostly T and B lymphocyte responses.
Examples are numerous and include the use of allogeneic
stem cell transplantation (SCT), monoclonal antibodies,
immune checkpoint inhibitors and cellular therapies (e.g.,
adoptive T cell transfer).8-10 However, accumulating evi-
dence has confirmed the significant impact of deregulated
interactions between host innate immune cells (e.g.,
monocytes, dendritic cells, and NK cells) and microbes
(e.g., chronic infections and dysbiosis) in the pathogenesis
of cancer.2,11-13 This seems especially true for lymphoid
malignancies, where antigenic stimulation by microbes
and chronic inflammation drive lymphoproliferation and
hence tumor progression.14 Moreover, the immunosup-
pressive environment that develops in many hematologi-
cal malignancies, consists of a considerable part of func-
tionally altered innate immune cells, including myeloid-
derived suppressor cells (MDSC), that cause immune eva-
sion, progression and dissemination of neoplastic cells.15
Therefore, considering the pivotal role of the innate
immune system in the initiation and progression of hema-
tological malignancies, it might prove a valuable target for
prevention and treatment. One option would be exploit-
ing the recently discovered feature of innate immune
memory which can be induced, for instance, by a Bacillus
Calmette-Guérin (BCG) vaccination.5 By enhancing and
restoring the function of innate immune cells, clearance of
microbial and neoantigens can be achieved and the
immunosuppressive tumor microenvironment reversed.
In addition, by innate immune training, the infection inci-
dence might be reduced in the high-risk setting of cancer
therapy. 
In the review herein we summarize the current knowl-
edge on the concept of ‘trained immunity’, and hypothe-
size ways of extending this concept to the field of lym-
phoid malignancies.   
The concept of trained immunity: a novel type 
of immune memory
For decades the prevailing assumption has been that
immunological memory was a feature characterizing only
the acquired immune system. However, recent studies
have shown that the mammalian innate immune system
also exhibits adaptive properties compatible with
immunological memory, for which the term ‘trained
immunity’ has been proposed.5 On reinfection or rechal-
lenge with microbial ligands, prototypical innate immune
cells such as monocytes/macrophages exhibit enhanced
functionality with the release of pro-inflammatory
cytokines and effector functions e.g., phagocytosis (Figure
1).16,17 The training of monocytes/macrophages is mediat-
ed by the activation of pattern-recognition receptors by
microbe-associated molecular patterns (MAMPs) from
bacteria and fungi; for example dectin-1 by β-glucan, and
nucleotide-binding oligomerization domain-containing
protein 2 (NOD2) by components of the BCG vaccine.16-19
Several mechanisms are involved in the development of
innate immune memory, among which epigenetic histone
modifications (e.g., histone methylation and acetylation),
and autophagy play a central role. Monocytes are func-
tionally reprogrammed for either enhanced (training) or
decreased (tolerance) cytokine production, depending on
the type and concentration of MAMPs they encoun-
tered17,20-22 (Figure 1). The epigenetic reprogramming of
monocytes after MAMP stimulation results in functional
as well as morphological changes, including cell surface
marker modifications such as upregulation of TLR expres-
sion.17,20 Autophagy contributes to the process of ‘trained
immunity’ induced by a BCG vaccination, as pharmaco-
logical or genetic (autophagy gene polymorphisms) inhibi-
tion blocks the epigenetic programming of monocytes
from occuring.23
Natural killer (NK) cells belonging to the innate immune
system also display memory functions, mainly during viral
infections. Expression of the Ly49H receptor and
chemokine receptor CXCR6 seem to be of importance for
the memory characteristics of NK cells.24,25 In addition, epi-
genetic modifications with changes in promoter methyla-
tion status are a hallmark of adaptive NK cells.26,27 The
adaptive immune features of NK cells result in their long-
term activation and protection from infection or reinfec-
tion with both herpesviruses and also influenza.24-26,28 NK
cell training can also be achieved by BCG vaccination with
the induction of non-specific immune memory, as has
been shown in healthy volunteers.29
‘Trained immunity’ of innate immune cells provides
protection against reinfection in a direct T/B-cell-indepen-
dent manner. In addition, a more or less indirect effect on
the acquired immune system may also occur as mono-
cytes/macrophages and NK cells influence cells of the
adaptive immune system.1 For instance, after BCG vacci-
nation complex cytokine profiles are induced that include
elevated T-helper (Th) 1 cytokines like IFNγ and also inter-
leukin (IL)-4 (Th2), IL-17 (Th17), and IL-10.30-33 These
responses belong to the adaptive immune responses that
facilitate and contribute to infection control and vaccina-
tion efficacy. 
Important hallmarks of ‘trained immunity’ are the non-
specific nature and long duration of the enhanced immune
responses. Trained monocytes have been shown to circu-
late in the peripheral blood for up to 3 months after BCG
vaccination, and NK responses, e.g., release of IFNγ, are
also enhanced for months.16,29 Immune training of both
monocytes and NK cells induces protection from infec-
tious agents other than the primary stimulus. In vitro stud-
ies demonstrated an increased innate immune response
against a plethora of pathogens after BCG vaccination,
including Mycobacterium tuberculosis, Candida albicans, and
Staphylococcus aureus.16,29 Moreover, in vivo data exist from
large vaccination trials. In low birth weight children from
Guinea-Bissau, vaccination with BCG resulted in reduced
neonatal mortality, which was the result of a composite
effect consisting of reduced neonatal sepsis, respiratory
infections and fever.34 However, this protective effect did
not result in overall reduced infant mortality, suggesting
that it was most pronounced in neonates.6 An alternative
explanation, however, might be the fact that the longevity
of the training effect is in the order of months and proba-
bly not years, although data on the exact duration are lack-
ing. In Danish cohorts similar results were also achieved
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with BCG and smallpox vaccinations, significantly reduc-
ing the risk of hospitalization for most subgroups of infec-
tious diseases, especially respiratory tract infections.35,36
Intriguingly, non-specific protection might go beyond
infections, as the BCG vaccination has been shown to be
effective in treating carcinomas (e.g., bladder cancer or
melanoma).37 
Considering the protective effects of ‘trained immunity’
against infections, the concept might be exploited to
improve care for cancer patients who suffer from infec-
tions. The concept might even be more important in
malignancies whose pathogenesis entails exposure to
microorganisms (chronic antigenic stimulation) and
impaired innate and adaptive immune responses, hence
hematological, but in particular, lymphoid malignancies. 
Role for microbes in lymphoid malignancies
Complex interactions between microorganisms,
immune cells and cells exhibiting features of neoplastic
transformation eventually determine the development of
overt malignant disease. This intriguing interrelatedness of
biological events is especially encountered in those cir-
cumstances where immune cells themselves are the cells
at risk for malignant transformation, thus in the setting of
lymphoid malignancies including multiple myeloma
(MM), chronic lymphocytic leukemia (CLL) and malignant
lymphomas. These diseases constitute ‘exemplary mod-
els’ in which the role of ‘trained immunity’ can be
explored. 
Infections in patients with lymphoid malignancies
Patients with cancer suffer from an increased risk for
common and opportunistic infections that result from dis-
ease intrinsic and anti-cancer therapy-induced immune
deficiencies. The severity of these deficiencies and the
specific nature of the defects determine which infections
can be expected to occur in individual patients. An elabo-
rate review of this topic is beyond the scope of this article
and an overview can be found in a recent publication.38  
Malignant lymphomas and CLL significantly increase
the risk for serious infections.39,40 The cause of this
increased risk for infections is multifactorial. Early on, the
humoral immune abnormalities, resulting from B-lympho-
cyte dysfunction often accompanied by the emergence of
hypogammaglobulinemia, dominate, and infections are
caused mainly by viruses and encapsulated bacteria. With
the progression of the lymphoid malignancies T cell dys-
function occurs, which is often therapy-related, but not
exclusively, as early after diagnosis T cell defects/alter-
ations are already present.41,42 Malignant B lymphocytes
produce anti-inflammatory cytokines, like IL-10 and 
TGF-β, and indoleamine 2,3-dioxygenase that skew the
balance from a Th1/Th17 towards a regulatory (FOXP3) T
cell phenotype.43,44 Moreover, tumor cells express immuno-
suppressive ligands like programmed death-ligand 1 (PD-
L1) and PD-L2 that inhibit proliferation and activation of
effector memory T cells.41,45 In addition, the recruitment of
tumor supporting innate myeloid cells; including nurse-
like cells, tolerogenic DCs, tumor-associated macrophages
(M2-polarized) and MDSCs; to the tumor micro-environ-
ment occurs, which enhance the state of tolerance.43,46-49
Through these mechanisms, malignant B cells, besides
inhibiting anti-tumor immunity, also impair immune
responses that are crucial for the control of both common
and opportunistic pathogens. Treatment with anti-neo-
plastic drugs, including purine analogs, and monoclonal
antibodies, further impair specific cellular immunity with
an increased risk of opportunistic infections.
Infection-induced lymphoid malignancies
The role of microorganisms in the pathogenesis of can-
cer is increasingly appreciated. Several classical pathogens
have been implicated in the origin of specific hematologic
malignancies. The Epstein-Barr virus is exemplary. It is
responsible for the disease infectious mononucleosis,
which has also been associated with a diverse range of
malignant lymphomas in immunocompetent and
immunocompromised patients e.g., Burkitt lymphoma,
and post-transplant lymphoproliferative disorder.  Other
well-known examples are Helicobacter pylori, Borelia
burgdorferi, Coxiella burnetii and the hepatitis C virus
(HCV), which have been associated with marginal zone
lymphoma (MZL) and diffuse large B-cell lymphomas
(DLBCL).14,50 Some of these diseases can initially be treated
with antimicrobial agents with a considerable chance for
cure, despite the fact that they can be considered mono-
clonal lymphoproliferative disorders.51,52 
Beyond specific pathogens, it has been shown that
experiencing common community-acquired viral and bac-
terial infections early in life increases the risk for develop-
ing lymphoid malignancies later in life. Large epidemio-
logical studies have shown clear associations between
infections and monoclonal B-cell lymphocytosis (MBL)
and CLL, non-Hodgkin lymphoma (NHL), and MM.53-55
More recently, the commensal bacterial flora of the gut
(microbiota) has also been implicated in lymphomagene-
sis.12 
The expression of restricted immunoglobulin gene
repertoires/B-cell receptors (BCR) in CLL and malignant
lymphomas underscores a key role of an antigenic drive in
the initiation and perpetuation of lymphoproliferation;
mainly microbial antigens but also self-antigens released
on cell apoptosis.56-59 In CLL, over 30% of cases can be
grouped together based on the expression of stereotypic
BCRs with characteristic complementarity determining
region 3 (CDR3) amino acid sequences. As CDR3s are
most decisive for the antigen specificity of immunoglobu-
lins (Igs), this strongly suggests that distinctive antigens
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Table 1. Characteristics of innate and adaptive immune responses.
Cellular Polymorphonuclear T-lymphocytes, 
components cells, monocytes, macrophages, B-lymphocytes
dendritic cells, NK cells,
innate lymphoid cells
Humoral Complement, host defense Specific antibodies
components peptides e.g., defensins, 
natural antibodies
Time Early: minutes-hours-days Late: days-weeks
to activation
Recognition Non-specific or semi-specific Highly specific
(pattern-recognition (T-cell receptors
receptors) and antibodies) 
Immune Epigenetic Gene recombination
memory reprogramming: and clonal  expansion
trained immunity
Lasts for weeks to months Lasts for years to
decades
are involved in the development of subsets of CLL. It was
recently shown that a newly identified subset of CLL with
mutated IgVH heavy chain, expresses stereotypic BCRs
highly specific for β-(1,6)-glucan, a major antigenic deter-
minant of yeast and molds.60 The clonal B-cells of these
patients were shown to proliferate in response to β-(1,6)-
glucan, suggesting that the fungal microbiota can deliver
functional ligands in the process of CLL. 
Mechanisms involved in the neoplastic transformation
of lymphocytes by microorganisms include: the release of
genotoxic metabolites, antigen-driven lymphoprolifera-
tion, induction of chronic inflammation, impaired apopto-
sis, inactivation of the tumor suppressor gene p53, disrupt-
ed DNA repair, mitochondrial dysfunction, and oxidative
stress.12,14,61-63 Antigen-driven lymphoproliferation is impli-
cated in the pathogenesis of CLL and NHL, including
MZL, mantle cell lymphoma (MCL), follicular lymphoma,
and DLBCL (Figure 2).64 However, B-cells express many
other (surface) receptors involved in microbial antigen
recognition in addition to the BCR, including CD5 and
CD6 (CLL) and pattern recognition receptors like TLR1,
TLR2, TLR6, TLR7, TLR9, NOD1 and NOD2 (CLL,
NHL).65,66 Signaling through these receptors is exploited by
the malignant cells for their own survival, precisely as
shown for BCR activation. The TLRs expressed by CLL
cells, for instance, are functional, as upon stimulation, the
nuclear factor-κB signaling pathway becomes activated,
protecting CLL cells from spontaneous apoptosis.65 
Cancer-induced immune-suppression; cancer 
progression and infections
Many cancers facilitate their preservation and progres-
sion by protecting themselves against the host’s immune
surveillance armamentarium by inducing an immunosup-
pressive environment. The acquired immune system
seems most affected with pronounced deficits occurring in
anti-tumor T cell responses resulting from several interre-
lated mechanisms, as described above, with an important
role for the accumulation of immunosuppressive innate
myeloid cells (e.g., MDSC).15 T cells from CLL patients
exhibit deviant T cell subset distributions, and have func-
tional defects, including impaired ability to form immuno-
logical synapses, decreased proliferative capacity and an
impaired effector function.67,68 These functional defects
coincide with an increased expression of CD244, CD160,
and PD-1 on CLL-derived T cells, a phenotype that is sim-
ilar to the phenotype of exhausted T cells in chronic viral
infections.69 Targeting these immune checkpoints has been
a new approach in the treatment of malignant lym-
phomas, and is now being explored in large clinical stud-
ies.70 
Also relevant to anti-tumor immune responses are
immune cells belonging to the innate immune systems,
such as NK cells and monocytes/macrophages. Defects in
these immune effectors that contribute to cancer initiation
and progression have been increasingly described in lym-
phoid malignancies. For instance, NK cells found in the cir-
Trained immunity in hematology
haematologica | 2016; 101(12) 1463
Figure 1. Epigenetic regulation of memory-like activity of innate immune cells. The biological phenomena of endotoxin tolerance and trained immunity are depicted
in the illustration. Stimulation of monocytes and/or macrophages via pattern recognition receptors (PRRs), such as Toll-like receptor 4 (TLR4) or dectin-1, leads to
increased expression of pro-inflammatory genes. Decreased or increased responsiveness of these cells to subsequent PRR stimulation may then occur, depending
on the initial type of stimulus that the cell received. TLR4 stimulation with lipopolysaccharide (LPS) can induce a state of endotoxin tolerance (represented by the
red line), whereas the stimulation of dectin-1 with β glucan from Candida albicans leads to a state of trained immunity (represented by the blue line). Initial PRR
stimulation leads to trimethylation of histone H3K4 (H3K4me3) and global acetylation of histone H4 on promoters of pro-inflammatory genes. In the case of endo-
toxin tolerance, the removal of the stimulus results in the loss of activating marks and gene expression returns to basal levels. Following a second encounter with
the stimulus, ‘tolerized’ genes will not regain the H3K4me3 mark or acetylation, and will remain silent to stimulation. In the case of 'trained immunity', pro-inflam-
matory genes will retain enhancers marked with monomethylation of histone H3K4. A second stimulus will induce transcription factors to bind to the enhancers and
promoters of these genes, thereby promoting an increase in H3K4me3 and thus the expression of ‘trained’ genes.22 
culation of CLL patients appear to have several functional
defects, including impaired cytotoxic activity, possibly
because of the defective expression of the NKG2D co-
receptor.71 Moreover, the monocytic population of CLL
patients has an altered composition and monocytes exhib-
it deregulation of genes that are involved in phagocytosis
and inflammation.72 Higher numbers of non-classical
CD14+CD16++ monocytes are present that are known to
have immune suppressive features opposed to the classical
CD14++CD16– counterparts. Intriguingly, monocytes from
CLL patients exhibit the primary features of ‘endotoxin
tolerance’, including low cytokine production, high
phagocytic activity and impaired antigen presentation.73
The refractory state of these cells prohibits sufficient
inflammatory responses to occur after pathogens and can-
cer cells (‘tumor tolerance’). This introduces a new mech-
anism of innate immune failure that contributes to the sus-
ceptibility of CLL patients to infections and tumor pro-
gression.73 
Trained immunity in hematological malignancies
Evidence for ‘trained immunity’ in cancer therapy
Training the innate immune system seems feasible and
effective, as for decades BCG vaccination has been suc-
cessfully applied in the treatment of urothelial cell carcino-
mas and melanomas.37 Data from large epidemiological
studies and vaccination trials reveal circumstantial evi-
dence for a similar potential in hematological malignan-
cies. In a previous Danish case-cohort study it was shown
that BCG vaccination during infancy significantly reduces
the risk of developing lymphoma’s (HR 0.49 (95% CI:
0.26–0.93)).74 Mechanisms proposed, attempting to
explain this beneficial result, included the stimulating
effect of vaccination on immune surveillance of cancer and
the decreased incidence of infectious diseases involved in
lymphoma pathogenesis. Older studies have tested the
concept of the induction of anti-tumour immunity in
patients with AML by vaccination.75,76 However, these
studies were small, and although some small benefits
were shown, these data preclude drawing definite conclu-
sions. At least BCG vaccination in these patients did not
result in untoward complications.
The use of β-glucan as an immune adjuvant in the treat-
ment of solid and hematological malignancies has evoked
considerable interest for many years, as the MAMP shows
promising activity both in vitro and in vivo. The anti-tumor
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Figure 2. Antigen-driven B cell receptor (BCR) signaling in lymphoproliferative diseases. Chronic stimulation of the BCR by microbial antigens and autoantigens
results in the activation of several intracellular signaling pathways resulting in lymphoproliferation, reduced apoptosis, prolonged cell survival and disrupted cell
migration that can contribute to the emergence of lymphoid malignancies. HCV: Hepatitis C virus; H. pylori: helicobacter pylori; S. pneumoniae: streptococcus pneu-
moniae; mTOR: mechanistic target of rapamycin; BLNK: B cell linker protein; BTK: Bruton's tyrosine kinase; PLCγ2: phospholipase C Gamma 2; PI3K: phosphatidyli-
nositol 3-kinase; PIP3: phosphatidylinositol (3,4,5)-trisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PDK: protein kinase D; Ca: calcium; JNK: Jun
N-Terminal kinases; IKK: IκB kinase; PKC: protein kinase C; NFAT: nuclear factor of activated T-cells; NF-κB: nuclear factor kappa B; ATF2: activating transcription fac-
tor 2.
activity directly relates to signaling through dectin-1,77,78
suggesting that the innate and acquired immunity elicited
by β-glucan could be of therapeutic value. In a small phase
I/II study, twenty patients with advanced malignancies
who were receiving chemotherapy were additionally
treated with a β-(1,3)/(1,6)-D-glucan preparation.
Preliminary results showed that β-glucan was well tolerat-
ed in these patients and suggested a beneficial effect on
hematopoiesis. Moreover, one patient with a chemother-
apy-refractory malignant lymphoma achieved a partial
response.79  
Mechanisms of action
The concept of ‘trained immunity’ can be explored as a
new modality of cancer prevention and therapy, as well as
in infection control. The concept seems appropriate to
consider in the setting of lymphoid malignancies, and
three major mechanisms can be envisioned to contribute
to the effects of innate immune enhancement in this set-
ting (Figure 3).
1. Decreasing antigen-driven lymphoproliferation:
Many data support the hypothesis that malignant B
cells, found in CLL and NHL e.g., MZL and MCL, resem-
ble antigen-activated B cells and that ongoing antigen-
induced modulation of cell responses occur in the context
of antigen recognition by the BCR and affiliated receptors
(Figure 2). Inhibiting this signaling cascade has already
proven to be of clinical use with the introduction of potent
BCR inhibitors, e.g., ibrutinib, and therefore eradicating 
B-cell stimulating antigens and infectious antigens and
autoantigens may also alter the course of lymphoprolifer-
ative diseases. This might be achieved by 'trained immu-
nity', as monocytes and macrophages can be activated to
prevent many infections that have been implicated in the
pathogenesis of lymphoma. Since monocytes and
macrophages are also pivotal in apoptotic cell clearance,
training of these cells might contribute to autoantigen
eradication.80,81 
2. Reversing immune tolerance:
Innate immunity
Considering the contribution of monocytes that exhibit
‘endotoxin and tumor tolerance’ to tumor progression and
infection risk, the reversal of their refractory state by
‘trained immunity’ might prove clinically beneficial. An
increased tolerogenic state of monocytes and
macrophages has clearly been implicated in lymphoid
malignancies.82 Nevertheless, whether vaccination with
BCG or β-glucan can restore the balance and skew tumor
associated macrophages from the M2 towards a more M1
phenotype with beneficial anti-tumor characteristics,
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Figure 3. Concept of ‘trained immunity’ of the innate immune system in lymphoid malignancies. Training of innate immune cells, including monocytes/macrophages
and NK cells, with microbial ligands results in enhanced effector functions of these cells. By facilitating antigen eradication and restoration of tumor surveillance and
anti-tumor immunity, the succeeding events that would ultimately result in the development of lymphoid malignancies might be interrupted or at least delayed. In
addition, enhanced immunity will also prevent and reduce infectious complications. Ig: immunoglobin; BCR: B cell receptor; TLR: toll-like receptor; MDP: muramyl
dipeptide; BCG: Bacillus Calmette-Guérin; CMV: cytomegalovirus; NK: natural killer; PD-1L: programmed death-ligand 1; MDSC: myeloid-derived suppressor cells; Th:
T helper; TREG: regulatory T cell; IL-10: interleukin 10; TGF-β: transforming growth factor-beta; NOD2: nucleotide-oligomerization domain-containing protein 2.
remains to be proven. However, recently data have shown
that another type of immunosuppressive myeloid cell, i.e.,
MDSC, can be successfully reprogrammed by exposure to
β-glucan, resulting in the loss of its immunosuppressive
phenotype and gain of enhanced antigen presenting
capacities.83 
In addition, a therapeutic approach in which NK cell
immunity can be enhanced, for instance by BCG vaccina-
tion, may lead to an improved function of NK cells, there-
upon overcoming cancer-induced NK cell function
defects.29,84
Acquired immunity 
General T cell dysfunction and exhaustion contribute to
tumor tolerance and defective immune surveillance.
Training the innate immune system also influences T cell
activity and skewing of acquired immune responses
towards Th1 and Th17 phenotypes that contribute to anti-
tumor immunity.
Generation of adaptive NK cells
NK cells play a pivotal role during the treatment of
hematological malignancies, and their activity might be
enhanced by ‘training’. The adoptive transfer of ex vivo
generated autologous and allogeneic NK cells is being
explored for immunotherapy in the setting of lymphoid
malignancies.85,86 Interestingly, considerable evidence
exists for a close relationship between CMV infection post
SCT and relapse of AML, in which NK cells are deemed to
be the effectors. Moreover, CMV infection results in a
mature phenotype of NK cells which also have memory-
like features.87 Hence, the training of NK cells by exposure
to BCG or CMV antigens and/or cytokines ex vivo, might
be a novel approach for the optimization of NK cell based
immunotherapies.26
How to apply “trained immunity” in hematology patients?
The prevention of lymphoid, and maybe, myeloid
malignancies on the population might be achieved with
immune training. Vaccination programs have underlined
the effect of immune training and the impact on cancer
development.74 However, additional studies are needed
before standard vaccination can be introduced on a larger
scale.  But what about the individual patient? Can innate
immune training alter the course of manifest hematologi-
cal malignancies? Malignancies that rely on antigen-driven
proliferation, hence lymphoid malignancies, seem, at least
conceptually, the best candidates for innate immune train-
ing. The timing of immune training might, however, prove
crucial. The efficacy of this approach is probably at the
highest level early on in the disease process, when the
tumor burden is low and before tumor evolution has
resulted in BCR signaling, independent proliferation and
profound immune exhaustion. Moreover, applying a live
attenuated vaccine such as BCG, which is normally con-
sidered safe, might prove to be less safe in patients with
severely impaired T cell immunity. Alternatives, such as
gamma-irradiated BCG, may prove more desirable.88 Since
these severe immune deficits occur in late stage disease, an
early initiation of vaccinations must be pursued. Two con-
ditions therefore seem ideal for testing the concept of
innate immune training: MBL/early stage CLL and MZL.
Training the immune system might be most feasible by
applying the BCG vaccination. Considerable experience
exists with this old vaccination strategy and safety is hard-
ly an issue, even in vulnerable patients, including low birth
weight children. Currently no standard immune adjuvant,
which is based on β-glucan or MDP, exists, and consider-
able questions remain to be answered about the route of
administration, dosage and safety of these antigens.
Conclusion
Epigenetic reprogramming of innate immune cells results
in enhanced non-specific immunity and immune memory.
‘Training’ of the innate immune system is a novel concept
in immunology and infectious disease that may be exploit-
ed in hematological malignancies, especially lymphoid
malignancies, where antigen-driven lymphoproliferation
and immune impairments are the hallmarks of the disease.
Amelioration of infectious complications and cancer pro-
gression can be envisioned as goals of 'trained immunity' in
cancer therapy. Acknowledging the current limited data on
the effects of ‘trained immunity’, and the hypothetical sta-
tus, thus far, of the concept in the setting of clinical hema-
tology, further studies are mandatory.
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